Jeffries & Company has reduced its price target for Charles River Laboratories CRL from $37.00 to $33.00. Charles River Laboratories has implemented a stock buyback which is to be funded by existing cash, credit, and free cash flows.
Based on the fact that the Company did not fully use its last buyback authorization, the firm takes a conservative approach and believes that the Company will deploy only half of its $500M authorization.
Jefferies believes that corporate costs are expected to run at 5.5% - 6% of revenue. The Company has taken steps like implementing a new ERP system, Lean/Six Sigma programs etc. to reduce overhead and operate efficiently.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorNewsPrice TargetBuybacksIntraday UpdateAnalyst RatingsHealth CareLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in